No votes yet

Torsade de Pointes, Prolonged QT Intervals, and Patients With Cancer

Lisa Hartkopf Smith
CJON 2012, 16(2), 125-128 DOI: 10.1188/12.CJON.125-128

Many kinase inhibitors, chemotherapeutic agents, antiemetics, antibiotics, and antifungal agents can prolong QT intervals, placing the patient as risk for the life-threatening ventricular arrhythmia Torsade de pointes (Tdp). In addition, common electrolyte imbalances experienced by many patients with cancer compound the risk. Because numerous medications used in oncology and common electrolyte imbalances in patients with cancer increase the risk for Tdp, oncology nurses must be informed about this life-threatening arrhythmia.


AstraZeneca Pharmaceuticals. (2010). <i>Caprelsa® (vandetanib) tablets</i> [Prescribing information]. Wilmington, DE: Author.

Bayer Healthcare Pharmaceuticals. (2011). <i>Nexavar® (sorafenib tablets)</i> [Prescribing information]. South San Francisco, CA: Author.

Bristol-Myers Squibb. (2011). <i>Sprycel® (dasatinib) capsules, oral</i> [Current approved prescribing information]. Princeton, NJ: Author.

Celgene Corporation. (2011). <i>Istodax® (romidepsin) for injection</i> [Prescribing information]. Summit, NJ: Author.

Cephalon, Inc. (2010). <i>Trisenox® (arsenic trioxide)</i> [Package insert]. Frazer, PA: Author.

Drew, B. J., Ackerman, M. J., Funk, M., Gibler, W. B., Kligfield, P. L., Menon, V., … Zareva, W. (2010). Prevention of torsade de pointes in hospital settings. A scientific statement from the American Heart Association and the American College of Cardiology Foundation. <i>Circulation, 121</i>, 1047-1060. doi:10.1161/CIRCULATION AHA.109.192704

Eisai, Inc. (2011). <i>Halaven® (eribulin mesylate) injection</i> [Prescribing information]. Woodcliff Lake, NJ: Author.

Genentech USA. (2011). <i>Zelboraf® (vemurafenib) capsules, oral</i> [Prescribing information]. South San Francisco, CA: Author.

Huff, J. (2006). <i>ECG workout: Exercises in arrhythmia interpretation</i> (5th ed.). Philadelphia, PA: Lippincott Williams and Wilkins.

Krantz, M. J., Martin, J., Stimmel, B., Mehta, D., & Haigney, M. C. (2009). QT interval screening in methadone treatment. <i>Annals of Internal Medicine, 150</i>, 387-395.

Luderitz, B. (2009). Historical perspective of electrocardiophysiology. <i>Hellenic Journal of Cardiology, 50</i>, 3-16.

Manish, S., & Muster, H. A. (2010). Hypocalcemia. Retrieved from <a target="_blank" href='http://emedicine.medscape.com/article/241893-overview'>http://emedicine....

Mayorga, J., Richardson-Hardin, C., & Dicke, K. A. (2002). Arsenic trioxide as effective therapy for relapsed acute promyelocytic leukemia. <i>Clinical Journal of Oncology Nursing, 6</i>, 341-346. doi:10.1188/02.CJON.341-346

Muehlbauer, P. M., Thorpe, D., Davis, A., Drabot, R., Rawlings, B. L., & Kiker, E. (2009). Putting Evidence Into Practice: Evidence based interventions to prevent, manage, and treat chemotherapy and radiotherapy-induced diarrhea. <i>Clinical Journal of Oncology Nursing, 13</i>, 336-341. doi:10.1188/09.CJON.336-341

Novello, N. P., & Blumstein, H. A. (2010). Hypomagnesemia in emergency medicine. Retrieved from <a target="_blank" href='http://emedicine.medscape.com/article/767546-overview'>http://emedicine....

Pfizer, Inc. (2012). <i>Xalkori® (crizotinib)</i> [Prescribing information]. New York, NY: Author.

Polovich, M., Whitford, J. M., & Olsen, M. (Eds.). (2011). <i>Chemotherapy and biotherapy guidelines and recommendations for practice</i> (5th ed.). Pittsburgh, PA: Oncology Nursing Society.

sanofi-aventis. (2011). <i>Anzemet® (dolasetron mesylate)</i> [Package insert]. Retrieved from <a target="_blank" href='http://products.sanofi-aventis.us/Anemet_Injection/anzemetinj.pdf'>http:...

Stringer, J., Welsh, C., & Tommasello, A. (2009). Methadone-associated Q-T interval prolongation and torsade de pointes. <i>American Journal of Health System Pharmacists, 66</i>, 825-833.

U. S. Food and Drug Administration. (2010). FDA drug safety communication: Abnormal heart rhythms associated with use of anzemet (dolasetron mesylate). Retrieved from <a target="_blank" href='http://www.fda.gov/Drugs/DrugSafety/ucm237081.htm'>http://www.fda.gov/Dr...

Woosely, R. L. (2011). Drugs that prolong the QT interval and/or induce torsade de pointes. Retrieved from <a target="_blank" href='http://www.azcert.org/medical-pros/drug-lists/printable-drug-list.cfm'>h...

Zareba, W. (2007). Drug-induced QT prolongation. <i>Cardiology Journal, 14</i>, 523-533.